http://theytarget.com/caronavirus-vaccine-treatment-has-been-discovered/

Caronavirus vaccine treatment has been discovered

As the world struggles for Covid-19 outbreaks to control pharmaceutical companies and contained, he is struggling to compete against any re-pandemic or to develop treatments. The death toll continues to rise. The first death from SARS-CoV virus-2 in the United States were reported in Washington February 29 March to Johns Hopkins Center for Science and Systems Engineering Systems Engineering (CSSE), 3048 11 people died in 11 countries. worldwide (96% or 2914) in China.

89198 SSSC also reported confirmed cases in 67 countries, of which 80,026 (90%) in China and 86 in the US Of the confirmed cases, more than half (45,175) were obtained.

A new study for Genetic Engineering and Biotechnology News (GEN) has 35 development of active substances in North America, Europe and China. 35 treatments that include Gilead Sciences have received and advanced most public attention in recent days, has been developed by companies ranging from pharmaceutical giants such as Gl

February 28 published by the official Xinhua press: 234 clinical trials in the register of clinical trials in China, nearly half focus (105) to Covid-19 treatment

Many of these tests are in the 60 trials in the ClinicalTrials.gov their descriptions contain 19 Covid term and seven studies, whose descriptions contain SARS-CoV 2 on the list included. The site contains 331,715 American studies in 209 countries.

The report Xinhua, Wu Yuanbin, general manager of science and technology for social development with the Chinese Ministry of Science and Technology (MOST) announced today the release of guidelines for clinical trials of drugs and vaccines to combat ‘outbreak of the deadly virus. The policy priority marketed drugs whose efficacy has been demonstrated in animals and in vitro.

But as reuse of existing drugs is the world’s only arrow in developers quiver legendary medicine and health organizations listed in the treatment develops in Genesis 35 and / or Covid-19 clinical trial from drug makers and / or the authorities in the last week described. As some experimental treatments have not yet been identified or identified any care provided by the developer, followed by the name or description of the processing, the type of treatment, including the mechanism, and a brief overview of the update of the latest development status.

to allow an option was the day’s links to the latest news on GEN pages of clinical studies, supported by the US authorities.

In many cases, the Chinese authorities, hospitals and companies to study possible treatments outside the scope of its original developers. The first hospital in Changsha Xiangya Second Hospital and South Central University are the main sponsors Pharmaceutical Co. Hu_nan Haiyao in a clinical trial, combining job evaluation Nonferrous Beijing Biotech Genoa of a recombination alpha interferon (IFN-α) and the viral Abbvie Kaletra (see above) to eliminate SARS-CoV-2 in patients with Covid-19 study should begin with the Chinese authorities.

Another example pirfenidone idiopathic pulmonary drug sold by Roche and its subsidiary Genentech fibrosis as-you Esbriet® used in patients Covid-19 heavy criticism in a randomized, open-label clinical program were prospectively recorded by the hospital to be examined Tongji, Tongji Medical College, Huazhong University of Science and technology.

Two other new partnerships focused on the crown of potential targets. Israel Institute for Biological Research, a government research institute, said on Feb. 25, the potential of the platform for the international gene expression Dyadic C1 expressed gene sequences and goals of the Foundation develops explore a candidate rVaccine and monoclonal antibodies for the treatment Covid- 19:01 day earlier, have co -crystal Pharma agreed to license proprietary antiviral compounds Covid array 19 and Norovirus Research Foundation of State University of Kansas. Co-crystal technology is designed to generate a 3D structure almost complex inhibitors with atomic resolution,

And unless foci on January 28 announced a partnership on a promising future treatment Platform: AbCellera said reaction platform ready to develop medical partners pandemic against field measurements within 60 days of isolation of an unknown viral pathogens. These partners include researchers from the Center for Vaccine Research of the National Institute of Allergy and Infectious Diseases NIH (NIAID).

This list is sure to multiply in the coming weeks the health organizations around the world, governments and pharmaceutical companies to increase efforts against SARS-CoV-second

Abbvie

treatment:Kaletra (also marketed as Aluvia, lopinavir / ritonavir)

write:Protease inhibitor of HIV-1, in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and children between the ages of 14 days and older.

condition:China Health Commission approved Kaletra of pneumonia caused by SARS-CoV-2, announced Abbvie January 27 Abbvie donated RMB 10 million ($ 1.4 million) to the Chinese authorities Kaletra experimental approach to this growing health crisis public support. “

Health Commission of Henan Province announced on January 31 that the three cases of diagnosis of new cases of coronavirus infection in patients taking Kaletra, a combination of ritonavir and lopinavir confirmed won. From this point, the nucleic acid testing more than 20 confirmed cases of patients with coronavirus infected hospitals negative Zhejiang Province approved the Kaletra was Ascletis Pharma, which evaluated a combination therapy just ASC09 candidate and ritonavir (see below).

AIM lmmunotech

treatment:Ampligen ® (rintatolimod)

write:Immunomodulatory indicated for severe chronic fatigue syndrome

condition:AIM was lmmunotech said 27.er in February with matchmaking ChinaGoAbroad and advice to cross-border transactions with China in contact to allow talks with the Chinese government to facilitate the access of the drug candidate in China using AIM Ampligen® prophylactic / therapeutic early debut against Covid -19 doing business approval studies in China, and FDA approval under rules that allow the export to use experimental drugs in the event of a national emergency sudden and immediate. These AIM rules have FDA approval in Argentina to import Ampligen received in 2019 as a treatment for severe chronic fatigue syndrome.

Altimmune

treatment:intranasal vaccine designed single systemic dose provide immunity

write: The vaccine is based on technology patented vaccine platform Altimmune who use company NasoVax, manufacturers of vaccines against influenza candidate proven to develop the positive results of Phase IIa.

condition:On February 28, that the design and the synthesis completed Altimmune vaccine and animal moved and production. The vaccine clinical trials could begin in August The company also said it is “actively engaged in discussions with several potential partners.”

Bio Apeiron

treatment:APN01

write:human recombinant enzyme of angiotensin-2 conversion (rhACE2) for the treatment of acute lung injury, acute respiratory distress syndrome, and pulmonary hypertension developed.

condition:Apeiron called is based in Vienna, launched on February 26, a pilot project, the researchers have started clinical trials in China APN01 designed to treat patients with severe SARS-CoV-2 to be evaluated. The study will gather blind randomized treatment 24 patients for seven days to preliminary data on the effects of rhACE2 on organic results, physiological and clinical and safety. Angalpharma based in Suzhou, China coordinate clinical study, with support from DMED Pharmaceuticals, one CRO based in Shanghai.

Ascletis Pharma

treatment:Ganovo® (danoprevir) ritonavir; ASC09 and ritonavir; ASC09 and oseltamivir; Ritonavir and oseltamivir;

write:HIV protease inhibitors

condition:February 26 Ascletis said three patients treated with combination therapy Covid 19 Ganovo® (danoprevir) ritonavir hospital after ninth Nanchang was rejected. On 2 February, Ascletis said the company “medical institutions and medical researchers” in clinical trials evaluating the combination of ritonavir and ASC09 Ascletis Covid-19, contribute actively to a request. On 25 January, Ascletis applies to the State Administration of medical products and its Center for Drug Evaluation and ASC09 include ritonavir fixed-dose combination of national emergency process.

Tongji Hospital in China tester ASC09 combinations and Tamiflu (oseltamivir), ritonavir and Tamiflu (oseltamivir) Tamiflu and only appears in an essay in the ClinicalTrials.gov . Tamiflu is in the United States by Genentech, a member of the Roche group, which is distributed under license from Gilead Sciences. Moreover ASC09 currency and ritonavir and lopinavir and ritonavir combination a prospective study of the First Affiliated Hospital of Medical School at the University of Zhejiang registered.

Bayer and many Chinese manufacturers

treatment:Chloroquine phosphate (from Bayer under Resochin®)

write:Chloroquine phosphate salt, with a compound of the quinoline antimalarials, and anti-inflammatory. Resochin was discovered by Bayer and introduced into clinical practice in 1947 to treat malaria.

condition:In clinical studies with more than 10 hospitals in Beijing and evaluated in Guangdong province in southern China, and Hunan Province in central China, “According to Sun Yanrong, deputy director of China National Center for the Development of biotechnology, through the Ministry of Science and Technology (MOST), reported the official news agency Xinhua on Feb. 17 chloroquine and was found. A Chinese researchers reported on a study published Feb. 4 in cell research. Health conditions for China chloroquine in its latest guidelines for treatment of pneumonia by 19 Covid including eight Chinese companies have production and delivery of the drug Shanghai.

Beijing Staidson Biopharma and InflaRx

treatment:IFX-1

write: Anti-C5a monoclonal antibody was developed to Covid-19 and hidradenitis

condition:The Chinese authorities have approved clinical trial with IFX-1 as Covid-19 treatment in February.

Biocryst

treatment:Galidesivir (BCX4430)

write:nucleoside RNA polymerase inhibitors are designed to interrupt viral replication

condition: a broad spectrum of in vitro activity against more than 20 viral RNA and viral diseases CORONA families showed Toga, Bunya understand filoviruses, arena viruses, paramyxoviruses and flaviviruses.

BioXyTran

treatment:BXT-25

write:Anti-necrosis-glyco-polymer-drug, whose structure is hybrid molecules comprising the hemoglobin molecule and the chemical structure of the polymer exclusive. BXT-25 is the main applicant company develops a product to carry oxygen to the tissues when blood flow is blocked.

condition:Bioxytran based in Boston, said on February 5 that the partnership with exploring “international pharmaceutical company” for respiratory distress syndrome, acute syndrome BXT-25 for development as treatment (ARDS) in patients with end of a SARS-CoV second BXT-25 is 5000 times smaller than red blood cells, the MDX MDX Viewer Life Sciences companies use to evaluate the safety and efficacy of the drug.

Celularity and Sorrento Therapeutics

treatment:ZINC-001

write:,, the activity of natural killer cells from allogeneic cell therapy placenta derived from the shelf (NK)

condition:The company on January 30 launched a clinical cooperation manufacture and design for the therapeutic use of Celularity extend CYNK-001 Covid-19 Sorrento and Celularity agree on a potential treatment for the new coronavirus, SARS-CoV 2 to specifically evaluate CYNK-001. Sorrento has 25% -Celularity decided to implement the existing capacity on the day of treatment with cGMP plant cell production in San Diego to use new systems to cGMP Celularity in Florham Park, New Jersey. Sorrento, already said he is in contact with the “leaders” of Chinese scientists and local experts of clinical validation requirements and logistics to discuss CYNK-001 track too fast in China.

Zhejiang Hisun Pharmaceutical and Chugai Pharmaceutical

treatment:tocilizumab

write: Reporting humanized interleukin-6 mAb

condition: 94 test, which assesses the patient tocilizumab recorded from the First Affiliated Hospital of University of Science and Technology of China (Anhui Province Hospital) with the Chinese authorities .

CSL and the University of Queensland

treatment:vaccine

write: designated vaccine does not specify its subsidiary proprietary adjuvant technology based Seqirus “MF59®

condition:February 12 CSL said it provides the know-how and MF59 University of Queensland donate in preclinical development program. University of adjuvant used to test the viral protein that develop molecular technology is tightened, the CSL. The company has participated in the $ 1 million yuan ($ 143,000) for the Red Cross Society of China in response to the epidemic.

CureVac

treatment:mRNA vaccine

write: mRNA application platform vaccine vaccine development CureVac

condition:CureVac cooperation and public-private coalition to product innovation for epidemics (CEPI), to develop a vaccine against SARS-CoV-2, said the partners strengthen their partnership on January 31, is to develop a vaccine rapid response platform. CEPI has will be needed 8.3 million in additional funding for the accelerated development, production and $ clinical trials. CEPI CEO Richard Hatchett said coalition and CureVac strive pathogenic genetic sequence of a vaccine candidate agents for clinical trials within a few months to bring. “

Cytodyn

treatment:Leronlimab (PRO 140)

write:Humanized IgG4 monoclonal antibody. Leronlimab is the main candidate Cytodyn and is a CCR5 antagonist with potential for multiple therapeutic indications.

condition:Cytodyn to offer plans with analysts on March 5 on its planned IND protocol and the clinical phase II study with the FDA an update during a conference call, the company investigated the treatment leronlimab considered a penny. Cytodyn Lung Group and China said they leronlimab as a potential treatment for cancer Crown and start exploring on 12 February.

Leronlimab completed nine clinical trials involving more than 800 people, according Cytodyn, including the fulfillment of the main goals of a Phase III study in combination with conventional anti-retroviral therapy for patients already infected with HIV. Cytodyn said a BLA schedule file with the FDA for HIV in the first quarter of 2020 Leronlimab fast designations persecuted by the FDA as a combination therapy with highly active antiretroviral therapy (HAART) in HIV patients are infected, and triple negative metastatic breast cancer.

Fujifilm Holdings and Zhejiang Hisun Pharmaceutical

treatment:Favipiravir (sold by Fujifilm as Avigan and Hisun China Favilavir)

write:Broad-spectrum antiviral that selective and develop potent inhibition of RNA-dependent RNA polymerase (RdRp) for the RNA-virus. Japan approves novel Avigan or reemerging flu and is already in use in Guinea Ebola patient to be treated.

condition:Minister for Health in Japan Katsunobu Kato said on February 22 that his ministry had recommended Avigan developed chemical Fujifilm Toyama, were effective for use as a corona treatment at test doses in mild and asymptomatic cases at least two medical facilities. In China, the National Board of Health approved on February 17, the version of Hisun drug as an experimental treatment for SARS-CoV-2 in an upcoming trial in Shenzhen.

Generex biotechnology

treatment:ii-Key peptide vaccine

write: Generex vaccine based on Ii-key platform of immune activation technology

condition:Generex said on February 27 China signed an agreement on the exchange of technology, Beijing Zhonghua Investment Fund Management Co. Ltd., Biology Institute of Shandong Academy of Sciences and has received international Sinotek-supports the development of industry (Shenzhen) Co. Ltd., a developer key II vaccine. Generex said $ 1 million already given the project work in the United States, a charge of $ 5,000,000 for Ii-Key technology, payment of the Chinese consortium for all costs and expenses to start developing a vaccine Covid -19 and a picture of 20 % in each vaccine dose produced.

Gilead Sciences

treatment:Remdesivir (GS-5734)

write: nucleotide prodrug

condition:NIH held on February 25, the first process is Covid-19 made an experimental treatment for patients remdesivir at the University of Nebraska Medical Center in Omaha assessment where some Americans dealt with the disease or quarantine assessment of the US. Remdesivir shows “adverse events” when given in the first confirmed infection with SARS-CoV US-2, members of the government investigation team Ncov Case 2019 in Washington said in January 31 in The New England Journal of Medicine.

In China According to the National Administration of medical products in China, have applications approved Hospital friendship between China and Japan and the Chinese Academy of Medical Sciences to perform the exams. Remdesivir and chloroquine . Chinese research team reported on a study published in the February 4 cell research.

GlaxoSmithKline and biopharmaceutical Klee

treatment:Covid-19 S-trimer

write:Coronavirus vaccine based on proteins

condition:GSK has agreed clover with an adjuvant system for a pandemic for more trimer S evaluation in preclinical studies to provide the company on February 24 as part of a research whose value was not disclosed. GSK reasons that clover can quickly and large quantities could bolster a new vaccine against the coronavirus, because it has a bigger house, a cGMP-scale commercial production capabilities of biopharmaceutical products in China.

“GSK is a world leader in vaccines, and in cooperation with them is greatly to the development stimulates expectations in time a vaccine, and the ability to produce sufficient amounts needed to address the epidemic Crown,” Michael Breen said conductor infectious diseases, pharmaceuticals globally.

Ibio and Beijing CC-pharming

treatment:vaccine

write: Plant Vaccine to FastPharming Ibio ™ production system

condition:The Company announced on February 3, development and testing a Covid-19 vaccine, the combination vaccine R & D experience, including work on MERS-Corona Chair CC-pharming and chief scientist Kevin Wang, Ph.D. and Ibio VP Upstream Bioprocessing Sylvain Marcel, PhD, in the rapid design of methods based expression systems for biopharmaceutical manufacturing production in plants. If successful, the candidate will search product built for production in manufacturing plants FastPharming Ibio in 2010 with funding from the Defense Advanced Research Projects Agency (DARPA) plants built are given, able to deliver to the medical act quickly in response to a pandemic,

The antibody ImmunoPrecise

treatment:The vaccines, and neutralizing antibodies crown

write: Prophylactic and therapeutic compounds of the transgenic platforms for detection of assets with ImmunoPrecise (including B cells and long display Select ™ ™) and subsidiary access ImmunoPrecise talem Therapeutics OmniAb® human animal platform for the direct production of antibodies.

condition:ImmunoPrecise announced their commitment to finding treatments on February 20 Covid-19 and said that he had asked Ilse Roodink, Ph.D., Chairman of the Scientific Committee on talem, as head of Global Crown project.

Incyte, Shanghai Hengrui Pharmaceutical

treatment:To and thymosin

write:The monoclonal antibodies to PD-1 humanized (Camrelizumab); 5-Da polypeptide hormone secreted by the thymus gland (thymosin)

condition: Chinese clinical studies, the combination treatment recorded from hospital Jinyintan Wuhan (Wuhan Hospital for Infectious Diseases) And University of the South.

pharmaceutical innovation

treatment:Brilacidin

write:Defensin camouflage in the development of the Phase II oral mucositis in patients with head and neck

condition:Innovation, said on February 24 that a transfer agreement material with “American virology lab managers” Brilacidin unexamined identified as a potential new treatment for SARS-CoV-2 showed. If the laboratory tests are successful, he said that innovation, research and clinical development Brilacidin accelerate “pharmaceutical associations, scientific cooperation and public grants.” Innovation also has a preliminary Brilacidin potential for the treatment of biomedical research and crown Development Authority (BARDA) advanced Synthesis.

Inovio Pharmaceuticals and Biotechnology Beijing Advaccine

treatment:INO-4800

write:vaccine

condition:Inovio said on January 30 that will benefit from the experience of Beijing Advaccine biotechnology to develop a Phase I study in China alongside the efforts of the clinical development of the company in the US to start treatment INO-krone 4800: e company said that developed INO-4800 in phase started in the US trials and used for the manufacture of medical devices preclinical studies. INO-4800 development is supported by a grant of $ 9,000,000, the Coalition for the production of innovation for epidemics (CEPI).

Janssen Pharmaceutical Cos. (Johnson & Johnson)

treatment:Prezcobix ™ (darunavir and cobicistat); The vaccine was developed with BARDA

write:HIV protease inhibitors (Prezcobix); the type of vaccine developed

condition:Janssen said Jan. 29 that 300 boxes Prezcobix hospital in Shanghai and Public Health Zhongnan Hospital of Wuhan University for use in research supports efforts be donated to find a solution to SARS CoV-second 50 additional cases have been asked to the Centers for Disease Control and Prevention for laboratory tests. Prezcobix in a study sponsored by the Shanghai Public Health Clinical Center studied Even if a Chinese test Precobix lopinavir or ritonavir-evaluated in combination with thymosin a1 .

Moreover, cooperation with the Authority for Advanced Biomedical Research and Development (BARDA) Janssen said Feb. 11:01 vaccine against SARS-CoV-2 development was expanded. The partners have agreed to Covid-19 Janssen Research accelerating costs for research and development and the know-how to share using vaccines in clinical trials. Janssen said that the discovery of potential treatments Covid-19 to speed, also in close contact with international partners working on the screen its library of antiviral molecules.

LinearX (Applied DNA Sciences) and Takis Biotech

treatment:Linear DNA Vaccine

write:developed on the basis of the PCR product for neutralizing antibodies to linear DNA to induce SARS-CoV-2

condition:LinearX a subsidiary of Applied Sciences DNA Stony Brook, New York, and Rome-based Takis Biotech said on Feb. 7, has formed a joint venture to develop based on a preclinical vaccine using TWO production technology, PCR, DNA has been identified to take all trade in the market for vaccines crown partners, the company said.

Company said the advantages of the technology is the speed of production, the absence of antibiotics and their resistance genes, DNA purity, simplicity of construction, the immunogenicity of an effective vaccine tried -Dessus linear DNA, the absence bacterial contamination and the effectiveness of the vaccine gene into in the patient’s genome without insert.

modern

treatment:mRNA 1273

write: New lipid nanoparticle (LNP) vaccine against mRNA -encapsulated Covid-19 a pre-fusion form of the stabilized spike protein (S) coded.

condition:By the National Institute for use in a phase I expected NIH of Allergy and Infectious Diseases (NIAID), the United States, the primary objective of the study scope, open-label phase I trial testing dose The patient is not yet the time limit trade recruited, the safety and reactogenicity of the vaccine 2 mRNA healthy 1,273 doses, treated with 28-day intervals 3 doses in adults to evaluate. Modern developed the vaccine in collaboration with researchers at the NIAID Vaccine Research Center (VRC).

NanoViricides

treatment: Antiviral treatment is based on the new corporate culture platform nanomedicine.

write: Virus ligand binding spectrum “E ‘as a virus, Venusfliegenfalle'” Anil R. Diwan, PhD, President and CEO, said.

condition:NanoViricides confirmed 30 gene 19:01 Covid treatment was developed, the fact that “already found lead candidate ligands chemical library” that it is capable of binding to the SARS-CoV spike protein in the same way tie with an affinity for ACE2 receptors.

The NanoViricides “technology is based on the copy of the receptor on human cell surface that bind to the binding agent virus is chemically bonded to a nanomicelle to create a nanoviricide®. If a virus is contacted with developer nanoviricide nanomicelle polymer fuse with the housing lipid virus.

The company said it “threatened” to test the potential candidates in cell culture against Corona, including those with the ACE2 receptor in a BSL-2 laboratory of Virology has started working as a campus in Shelton, CT. NanoViricides said it is working to develop partnerships Covid-19 promotion program should be an effective drug candidate identified.

Novavax

treatment:select vaccine candidates

kind of: Developing vaccines for nanoparticle technology platform companies employ proprietary recombinant protein antigens derived from the protein Crown spike (S) to generate. Novavax said it plans to expand its Covid-19 adjuvant to strengthen Matrix-M ™ saponin with potential vaccines using immune response.

condition:“Now that we are well positioned to stage vaccine candidates Covid-19 to promote clinical trials in May or June I,” said President and Chief Executive Stanley C. Erck February 26 a statement. Novavax has cited progress in the development, he said, it has created, and currently more nanoparticle vaccine candidates in animal models to identify ahead of an ideal candidate to test evaluated in humans.

Pharmstandard

treatment:Arbidol (umifenovir)

write:membrane fusion inhibitor developed for the treatment of influenza

condition:Pharmstandard evaluated clinical studies in monotherapy and in combinations, including Arbidol Abbvie Kaletra (see above), the ASC09 Ascletis Pharma (see above), lopinavir, ritonavir and carrimycin bromhexine hydrochloride (post invitation). Arbidol five included studies are listed in ClinicalTrials.gov. China Ruijin Hospital behavioral testing alone While several Chinese hospitals investigate combination therapies.

Q Biomed research and Mannin

treatment:Drugs for the treatment of vascular disease in humans with Covid-19

write:Further treatment of vascular leakage and endothelial dysfunction observed in Covid-19 and other infectious diseases that develop from the main platform Wortmannin Research Partners designed the target signal angiopoietin-Tie2 activation.

condition:Q Biomed research and Mannin announced their cooperation on February 4th 2019. In September, the German state of Saxony awarded Mannin about $ 7.7 million ahead of its therapeutic products, including medicines and biological that reduces endothelial dysfunction and loss of integrity of the endothelial barrier . to examine Mannin recently signed a funding request for the transfer of technology from NIH small business gives Mannin platform-specific therapeutic applications.

Regeneron Pharmaceuticals

treatment:REGN3048 and RAIN 3051

write: Combination of monoclonal antibodies which neutralize the part of the monoclonal antibody discovery platform technology company Regeneron VelocImmune® VelociSuite called to enjoy.

condition:On 4 February, research and development, said Advanced Biomedical (BARDA) Authority has a cooperation agreement to expand with Regeneron before developing “monoclonal antibodies longer be used alone or in combination, can be treated with new treatments.” The combination has a Phase I study completed in the Middle East respiratory syndrome coronavirus in the past year.

Sanofi

treatment:No Name vaccine

write:Sanofi vaccine based on recombinant DNA platform designed to produce found an exact match to the genetic proteins on the virus surface. Sanofi, the DNA sequence coding for the antigen with the DNA of the baculovirus expression combined platform and is used to rapidly transmit large amounts of crown-antigen formulated to enhance the immune system for protection against the virus.

condition:Sanofi said Feb. 18 that the global business unit Sanofi Pasteur vaccine worked in a real Covid-19 at speed through cooperation with the Authority before the development of a vaccine against SARS vaccines, development of advanced biomedical technologies and development (BARDA). In clinical studies, the candidate SARS vaccine was immunogenic and offered partially evaluated in animal models of a challenge protection, says Sanofi. This work Basic Sciences proteins, acquired in 2017 by Sanofi “Covid-19 vaccine a speed advantage,” said Sanofi.

keeping the pharmaceutical tonix

treatment:TNX-1800

write: Modified shot vaccine percutaneous live horsepox

condition:Tonix said Feb. 26 with Southern research TNX-1800 contact was like a vaccine treatment for developing Covid-19 TNX-1800 developed as much as possible as a vaccine against smallpox, to avoid that the reserves US national strategic and as a vaccine to prevent monkeypox.

Vaxart

treatment:A vaccine based on exclusive VAAST ™ Platform

write:recombinant vaccine administered by oral tablet

condition:Vaxart 31 said Jan. it expects vaccine candidates based on genome 2019-19 released to produce Covid (Ncov SARS-2) and evaluated in preclinical models for their ability to produce both the mucosal immune response and systemic.

Vir Biotechnology and Biological Wuxi

treatment:Still to be silent human monoclonal antibody

write:human monoclonal antibodies bind to the SARS-CoV-2, isolated from people who had survived severe infections, acute respiratory syndrome (SARS).

condition:announced Vir Biotechnology February 25 cooperation with development and production of biological products before the Wuxi production of human monoclonal antibodies as potential treatments for Covid-19 antibodies were discovered antibodies through enterprise platform that was used antibodies pathogens, including Ebola (mAb114, which force in Congo) to detect the virus and develop hepatitis B, influenza, malaria and others when antibodies obtain regulatory approvals, Wuxi therapies biological entitled to sell in greater China and Vir, in all other markets around the world.

[/pl_text]
[/pl_col]
[/pl_row]